Humoral signatures of MOG-antibody-associated disease track with age and disease activity

M Spatola, O Chuquisana, W Jung, JA Lopez… - Cell Reports …, 2023 - cell.com
M Spatola, O Chuquisana, W Jung, JA Lopez, EM Wendel, S Ramanathan, CW Keller…
Cell Reports Medicine, 2023cell.com
Myelin oligodendrocyte glycoprotein (MOG)-antibody (Ab)-associated disease (MOGAD) is
an inflammatory demyelinating disease of the CNS. Although MOG is encephalitogenic in
different mammalian species, the mechanisms by which human MOG-specific Abs contribute
to MOGAD are poorly understood. Here, we use a systems-level approach combined with
high-dimensional characterization of Ab-associated immune features to deeply profile
humoral immune responses in 123 patients with MOGAD. We show that age is a major …
Summary
Myelin oligodendrocyte glycoprotein (MOG)-antibody (Ab)-associated disease (MOGAD) is an inflammatory demyelinating disease of the CNS. Although MOG is encephalitogenic in different mammalian species, the mechanisms by which human MOG-specific Abs contribute to MOGAD are poorly understood. Here, we use a systems-level approach combined with high-dimensional characterization of Ab-associated immune features to deeply profile humoral immune responses in 123 patients with MOGAD. We show that age is a major determinant for MOG-antibody-related immune signatures. Unsupervised clustering additionally identifies two dominant immunological endophenotypes of MOGAD. The pro-inflammatory endophenotype characterized by increased binding affinities for activating Fcγ receptors (FcγRs), capacity to activate innate immune cells, and decreased frequencies of galactosylated and sialylated immunoglobulin G (IgG) glycovariants is associated with clinically active disease. Our data support the concept that FcγR-mediated effector functions control the pathogenicity of MOG-specific IgG and suggest that FcγR-targeting therapies should be explored for their therapeutic potential in MOGAD.
cell.com